Rita D. Swinford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rita D. Swinford has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ronald J. Portman
Pediatric Center of Excellence
2 shared publicationsAmr Elgehiny
Department of Pediatrics, University of Texas Health Science Center at Houston
1 shared publication- Christian L. Erikson
Department of Pediatrics, Division of Critical Care Medicine, Texas Children’s Hospital, The Woodlands 17600 I-45 South, WL 640, Conroe, TX, USA
1 shared publication - Cynthia S. Bell
University of Texas McGovern Medical School at Houston
1 shared publication Ellen M Grimm
Pediatric Nephrology and Hypertension, University of Texas-Houston, Medical School, Houston, USA
1 shared publication- Esraa Elsamny
Department of Pediatrics, University of Texas Health Science Center at Houston
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1906970
Case Report: Sodium glucose cotransporter 2 inhibitor use in a pediatric patient with cancer receiving cisplatin
Cisplatin is a foundation chemotherapeutic for pediatric germ cell tumors; however, its dose-dependent nephrotoxicity can limit use. Hypomagnesemia is a challenging side effect, and patients often remain hypomagnesemic despite IV and oral magnesium (Mg) supplementation. Sodium Glucose Cotransporter 2 inhibitors (SGLT2is) have been shown to mitigate cisplatin-induced nephrotoxicity (CIN) and reduce urinary Mg wasting in adults, but their use remains off-label and limited in pediatrics. We report a case of an adolescent male with metastatic germ cell tumor treated extensively with cisplatin, whose course was complicated by hypertension, hypomagnesemia, and a declining glomerular filtration rate (GFR). An SGLT2i was started three months into treatment. His GFR stabilized and his proteinuria resolved despite continued treatment with cisplatin. Additionally, he discontinued IV Mg supplementation while maintaining adequate levels on oral Mg, and his blood pressure improved with discontinuation of antihypertensives. This case highlights a potential role of SGLT2is in pediatric oncology.
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1906970
Open AccessCase Report: Sodium glucose cotransporter 2 inhibitor use in a pediatric patient with cancer receiving cisplatin
Cisplatin is a foundation chemotherapeutic for pediatric germ cell tumors; however, its dose-dependent nephrotoxicity can limit use. Hypomagnesemia is a challenging side effect, and patients often remain hypomagnesemic despite IV and oral magnesium (Mg) supplementation. Sodium Glucose Cotransporter 2 inhibitors (SGLT2is) have been shown to mitigate cisplatin-induced nephrotoxicity (CIN) and reduce urinary Mg wasting in adults, but their use remains off-label and limited in pediatrics. We report a case of an adolescent male with metastatic germ cell tumor treated extensively with cisplatin, whose course was complicated by hypertension, hypomagnesemia, and a declining glomerular filtration rate (GFR). An SGLT2i was started three months into treatment. His GFR stabilized and his proteinuria resolved despite continued treatment with cisplatin. Additionally, he discontinued IV Mg supplementation while maintaining adequate levels on oral Mg, and his blood pressure improved with discontinuation of antihypertensives. This case highlights a potential role of SGLT2is in pediatric oncology.
- Open Access
- 3 August 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 1-4
Thrombotic microangiopathy associated with Valproic acid toxicity
Thrombotic microangiopathy (TMA) is a serious, sometimes life-threatening disorder marked by the presence of endothelial injury and microvascular thrombi. Drug-induced thrombotic microangiopathy (DI-TMA) is one specific TMA syndrome that occurs following drug exposure via drug-dependent antibodies or direct tissue toxicity. Common examples include calcineurin inhibitors Tacrolimus and Cyclosporine and antineoplastics Gemcitabine and Mitomycin. Valproic acid has not been implicated in DI-TMA. We present the first case of a patient meeting clinical criteria for DI-TMA following admission for valproic acid toxicity. An adolescent male with difficult to control epilepsy was admitted for impaired hepatic function while on valproic acid therapy. On the third hospital day, he developed severe metabolic lactic acidosis and multiorgan failure, prompting transfer to the pediatric intensive care unit. Progressive anemia and thrombocytopenia instigated an evaluation for thrombotic microangiopathy, where confirmed by concomitant hemolysis, elevated lactate dehydrogenase (LDH), low haptoglobin, and concurrent oliguric acute kidney injury. Thrombotic thrombocytopenic purpura was less likely with adequate ADAMTS13. Discontinuing valproic acid reversed the anemia, thrombocytopenia, and normalized the LDH and haptoglobin, supporting a drug-induced cause for the TMA. To the best of our knowledge, this is the first report of drug-induced TMA from valproic acid toxicity.
- 3 August 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 1-4
Open AccessThrombotic microangiopathy associated with Valproic acid toxicity
Thrombotic microangiopathy (TMA) is a serious, sometimes life-threatening disorder marked by the presence of endothelial injury and microvascular thrombi. Drug-induced thrombotic microangiopathy (DI-TMA) is one specific TMA syndrome that occurs following drug exposure via drug-dependent antibodies or direct tissue toxicity. Common examples include calcineurin inhibitors Tacrolimus and Cyclosporine and antineoplastics Gemcitabine and Mitomycin. Valproic acid has not been implicated in DI-TMA. We present the first case of a patient meeting clinical criteria for DI-TMA following admission for valproic acid toxicity. An adolescent male with difficult to control epilepsy was admitted for impaired hepatic function while on valproic acid therapy. On the third hospital day, he developed severe metabolic lactic acidosis and multiorgan failure, prompting transfer to the pediatric intensive care unit. Progressive anemia and thrombocytopenia instigated an evaluation for thrombotic microangiopathy, where confirmed by concomitant hemolysis, elevated lactate dehydrogenase (LDH), low haptoglobin, and concurrent oliguric acute kidney injury. Thrombotic thrombocytopenic purpura was less likely with adequate ADAMTS13. Discontinuing valproic acid reversed the anemia, thrombocytopenia, and normalized the LDH and haptoglobin, supporting a drug-induced cause for the TMA. To the best of our knowledge, this is the first report of drug-induced TMA from valproic acid toxicity.
- 19 October 2015
- Published by Springer Nature in Current Cardiology Reports
- Vol. 17 (12) , 1-8
Management of Hypertension in Children and Adolescents
Hypertension in children and adolescents is becoming a greater problem in the developed world. Although traditionally thought of as usually secondary to renal, vascular, or endocrine causes, primary hypertension is becoming the most common form seen in childhood. This changing epidemiology is related to the recent obesity epidemic. The evaluation of high blood pressure in children is more involved than in adults and is aimed both at identifying secondary causes and to identify other co-morbidities of cardiovascular risk. Treatment of hypertension in childhood and adolescence is aimed at reducing cardiovascular risk. While there are a growing number of antihypertensive agents with FDA labeling for children, there remain far fewer options than for adults. This paper reviews the epidemiology, definitions, evaluations, and management of elevated blood pressure in children and adolescents.
- 19 October 2015
- Published by Springer Nature in Current Cardiology Reports
- Vol. 17 (12) , 1-8
Management of Hypertension in Children and Adolescents
Hypertension in children and adolescents is becoming a greater problem in the developed world. Although traditionally thought of as usually secondary to renal, vascular, or endocrine causes, primary hypertension is becoming the most common form seen in childhood. This changing epidemiology is related to the recent obesity epidemic. The evaluation of high blood pressure in children is more involved than in adults and is aimed both at identifying secondary causes and to identify other co-morbidities of cardiovascular risk. Treatment of hypertension in childhood and adolescence is aimed at reducing cardiovascular risk. While there are a growing number of antihypertensive agents with FDA labeling for children, there remain far fewer options than for adults. This paper reviews the epidemiology, definitions, evaluations, and management of elevated blood pressure in children and adolescents.
- 15 November 2010
- Published by Springer Nature
- p. 499-515
Evaluation of the Hypertensive Pediatric Patient
- 15 November 2010
- Published by Springer Nature
- p. 499-515
Evaluation of the Hypertensive Pediatric Patient
- 1 April 1998
- Published by Springer Nature in Pediatric Research
- Vol. 43 (4) , 308
The Safety and Efficacy of the Calcium Channel Blocker (CCB) Amlodipine in the Treatment of Secondary Hypertension in Children † 1806
- 1 April 1998
- Published by Springer Nature in Pediatric Research
- Vol. 43 (4) , 308
The Safety and Efficacy of the Calcium Channel Blocker (CCB) Amlodipine in the Treatment of Secondary Hypertension in Children † 1806